Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Real world intracranial efficacy of trastuzumab deruxtecan (T-DXd, HER2 ADC) in HER2 mutant NSCLC.
Systemic RR 54.8%, PFS 7.2m, OS 18.3m across lines. As 1L, RR 72.2%, OS 22.1m. Intracranial RR 74.1% in 27 pts. ILD seen in 14% (4 fatal).”
Title: Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort
Authors: Oliver Illini, Anna-Carina Hund, Hans-Georg Kopp, Mor Moskovitz, Giannis Mountzios, Wolfgang Brueckl, Martin Früh, Marie-Elisabeth Leßmann, Petros Christopoulos, Albrecht Stenzinger, Michael Thomas, Roni Gillis, Nir Peled, Fabian Acker, Alfredo Addeo, Andriani Charpidou, Christian Grohé, Laetitia Mauti, Sacha Rothschild, Sabine Schmid, Christian Schumann, Damien Urban, Robert Wurm, Simon Ekman, Marcus Skribek, Franziska Glanemann, Marcel Wiesweg, Christoph Ackermann, Sofia Agelaki, Petra Hoffknecht, Marko Jakopović, Jens Kern, David König, Katharina Kostenzer, Cornelia Kropf-Sanchen, Eckart Laack, David Lang, Laurenz Nagl, Georg Pall, Martin Reck, Waleed Kian, Anna Allemann, Jürgen Alt, David Araújo, Alexandros Bokas, Fabikan Hannah, Julie Krainer-Jacobs, Christoph Weinlinger, Adrianus de Langen, Evangelos Fergadis, Elena Fountzilas, Patrizia Froesch, Nikolaj Frost, Frank Griesinger, Franziska Jordan, Charisios Karanikiotis, Barbara Kiesewetter, Ippokratis Korantzis, Andrea Lopes Machado, Panagiota Economopoulou, Arnold Pilz, Patrick Reimann, Achim Rittmeyer, Akram Saad, Konstantinos Samitas, Karsten Schulmann, Riyaz Shah, Jan Alexander Stratmann, Hossein Taghizadeh, Kai Tammoscheit, Amanda Tufman, Jan-Phillip Weber, Ewald Wöll, Arschang Valipour, Tobias Overbeck, Maximilian Hochmair
Read the Full Article.
Other articles featuring Stephen V Liu on OncoDaily.